Innovation

Development Pipeline

Development Pipeline

We are determined to drive breakthrough innovations for patients in diseases of high unmet medical need. In clinical development we are currently advancing more than 30 projects that we review regularly so that we can give priority to the most promising programs.

Pipeline Overview

The following table lists a selection of major Pharma portfolio projects that we are advancing through different stages of development.

 

More detailed information on individual programs, therapeutic areas, and development timelines as well as a one-page overview of our development portfolio can be found in our overview package for download.

 

phases

Number of programs in clinical development.

 

A woman in a white shirt smiles at the camera.
Dr. Julia Schulze
PhaseAreaProgram (Mode-of-action)Indication 
IIIONCDarolutamide
(AR Inhibitor)
Prostate Cancer
(mHSPC)
Small Molecule
IIIONCDarolutamide
(AR Inhibitor)
Adjuvant Prostate CancerSmall Molecule
IIIONCDarolutamide
(AR Inhibitor)
Prostate Cancer with
Biochemical Recurrence after
Curative Radionuclide Therapy
Small Molecule
IIICVDFinerenone
(MR Antagonist)
Heart Failure
(HFmr/pEF)
Small Molecule
IIICVDFinerenone
(MR Antagonist)
Non-diabetic CKDSmall Molecule
IIICVDFinerenone
(MR Antagonist)
Chronic Kidney Disease 
in Type 1 Diabetes 
FINE-ONE
Small Molecule
IIICVDVericiguat
(sGC Stimulator)
Heart Failure
(HFrEF)
Small Molecule
IIICVDAsundexian
(FXIa Inhibitor)
2 Stroke Prevention
(OCEANIC Stroke)
 
Small Molecule
IIIOtherElinzanetant
(Neurokinin-1,3 Rec Antag.)
Vasomotor SymptomsSmall Molecule
IIIOtherAflibercept 8mg
(VEGF Inhibitor)
Retinal Vein Occlusion
(QUASAR)
Biologic_NTE
IIIOtherGadoquatrane
(High Relaxivity Contrast Agent)
Magnetic Resonance
Imaging (HRCA-PAT)
Contrast Agent_NTE
IICVDCongestive Heart Failure rAAV Gene Therapy (AB-1002)Congestive Heart Failure
(GenePHIT)
gene therapy
IICVDAnti-a2APAcute Ischemic Stroke;
Pulmonary Embolism
Antibody
IIOtherRuncaciguat
(sGC Activator)
Non-prolif. Diabetic
Retinopathy (NPDR)
Small Molecule
IONCHER2/mEGFR InhibitorAdvanced Non-small
Cell Lung Cancer with
EGFR Mutation and/or
HER2 Mutation
Small_Molecule_NTE
IONCDGKzeta InhibitorAdvanced solid tumorsSmall_Molecule_NTE
IONCCCR8 AbAdvanced solid tumorsAntibody
IONCVVD Keap1 ActCancerSmall_Molecule_NTE
IONCDGKalpha InhibitorCancerSmall_Molecule_NTE
IONC225Ac-PelgifatamabAdvanced Prostate CancerRadiotherapy_NTE
IONCVVD STAT3 InhibitorCancerSmall_Molecule_NTE
IONC225Ac-PSMA-TrilliumAdvanced Prostate CancerRadiotherapy_NTE
ICVDsGC Activator OralChronic Kidney DiseaseSmall_Molecule_NTE
ICVDSEMA 3aAlport SyndromeAntibody
ICVDAnti-coagulantAnti-coagulationSmall_Molecule_NTE
INRDBemdaneprocel
(Parkinson’s Disease
Cell Therapy)
Parkinson's DiseaseCell Therapy_NTE
INRDParkinson‘s Disease
rAAV Gene Therapy
Parkinson’s DiseaseGene Therapy_NTE
INRDMultiple System Atrophy
rAAV Gene Therapy
Multiple
System Atrophy
Gene Therapy_NTE
INRDPompe Disease
rAAV Gene Therapy
Pompe DiseaseGene Therapy_NTE
INRDHuntington‘s Disease
rAAV Gene Therapy
Huntington‘s DiseaseGene Therapy_NTE
INRDLGMD2I/R9
rAAV Gene Therapy
Limb Girdle
Muscular Dystrophy
Gene Therapy_NTE
IOtherGPR84 AntagonistDiabetic
Neuropathic Pain
Small_Molecule_NTE
IOtherBAY 2701250Pulmonary HypertensionProtein Therapeutics

* Including Precision Cardiovascular, Nephrology & Acute Care

Legende_pipeline

 

New Molecular Entity   New molecular entity
Life cycle management   Life cycle management

 

Lisa Hennig
Lisa Hennig
Development